Rare "crisis signal" triggers for third time in U.S. market

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Jacob Frieberg Biography and Net Worth

Director of Vaccinex

Jacob B. Frieberg has served as a member of our board of directors since February 2015. Mr. Frieberg has also served as a principal at The WTF Group, a Toronto-based property management company, since founding the company in 1984. Prior to that time, he was the Vice President at Rockford Developments, a Calgary-based multi-family building company. Mr. Frieberg received a B.A. in Economics from the University of Western Ontario. We believe that Mr. Frieberg’s experience in business, including his management responsibility, gives him the qualifications, skills and financial expertise to serve on our board of directors.

How do I contact Jacob B. Frieberg?: The corporate mailing address for Mr. Frieberg and other Vaccinex executives is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. Vaccinex can also be reached via phone at (585) 271-2700 and via email at [email protected]. Learn More on Jacob B. Frieberg's contact information.
Has Jacob B. Frieberg been buying or selling shares of Vaccinex?: Jacob B. Frieberg has not been actively trading shares of Vaccinex during the last ninety days. Most recently, on Thursday, January 27th, Jacob B. Frieberg bought 429 shares of Vaccinex stock. The stock was acquired at an average cost of $233.10 per share, with a total value of $99,999.90. Learn More on Jacob B. Frieberg's trading history.
Who are Vaccinex's active insiders?: Vaccinex's insider roster includes Jacob Frieberg (Director), and Maurice Zauderer (CEO). Learn More on Vaccinex's active insiders.
Are insiders buying or selling shares of Vaccinex?: During the last year, Vaccinex insiders bought shares 5 times. They purchased a total of 204,992 shares worth more than $1,253,325.81. During the last year, insiders at the sold shares 1 times. They sold a total of 224 shares worth more than $2,257.92. The most recent insider tranaction occured on August, 9th when Director Albert Friedberg bought 100 shares worth more than $451.00. Insiders at Vaccinex own 51.5% of the company. Learn More about insider trades at Vaccinex.
Information on this page was last updated on 8/9/2024.

Jacob B. Frieberg Insider Trading History at Vaccinex

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/27/2022	Buy	429	$233.10	$99,999.90

Jacob B. Frieberg Buying and Selling Activity at Vaccinex

Vaccinex Company Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Today's Range

Now: $1.21

$1.00

$1.36

50 Day Range

MA: $3.23

$1.01

$4.59

2 Week Range

Now: $1.21

$0.76

$1.36

Volume

27,216 shs

Average Volume

75,650 shs

Market Capitalization

$3.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1